⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15668178 | 0.67 | PDPK1 (0.39) | — | |
| SCHEMBL38439 | 0.64 | — | — | |
| SCHEMBL15668177 | 0.62 | PDPK1 (0.38) | — | |
| SCHEMBL16878102 | 0.60 | — | — | |
| SCHEMBL383127 | 0.58 | KMT2A (0.44) | — | |
| SCHEMBL334792 | 0.58 | — | — | |
| SCHEMBL2862 | 0.57 | — | — | |
| SCHEMBL972087 | 0.56 | — | — | |
| SCHEMBL3899361 | 0.55 | — | — | |
| SCHEMBL16427307 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152670-B1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8202885-B2 | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-2152670-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008132679-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-06 | — | — | WO | disclosed |
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |